Literature DB >> 34064199

Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease.

Saki Kanda1, Yoshimitsu Fujii1, Shin-Ichiro Hori1, Taichi Ohmachi1, Ken Yoshimura1, Koichiro Higasa2, Kazunari Kaneko1.   

Abstract

Kawasaki disease (KD) is a systemic vasculitis with an unknown etiology affecting young children. Although intravenous immunoglobulin (IVIG) plus acetylsalicylic acid is effective in most cases, approximately 10-20% of patients do not respond to this therapy. An 8-month-old boy was admitted to a local hospital with the presumptive diagnosis of KD. He received IVIG twice and four series of methylprednisolone pulse therapy from the third to the tenth day of illness. Despite these treatments, his fever persisted with the development of moderate dilatations of the coronary arteries. A diagnosis of refractory KD was made, and infliximab with oral prednisolone was administered without success. Defervescence was finally achieved by cyclosporine A, an inhibitor of the signaling pathway of the calcineurin/nuclear factor of activated T cells (NFAT). Whole-genome sequencing of his deoxyribonucleic acid samples disclosed two single nucleotide variants (SNVs) in disease-susceptibility genes in Japanese KD patients, ORAI1 (rs3741596) and BLK (rs2254546). In summary, the refractory nature of the present case could be explained by the presence of combined SNVs in susceptibility genes associated with upregulation of the calcineurin/NFAT signaling pathway. It may provide insights for stratifying KD patients based on the SNVs in their susceptibility genes.

Entities:  

Keywords:  BLK; ORAI1; cyclosporine A; refractory Kawasaki disease; single nucleotide variant

Year:  2021        PMID: 34064199     DOI: 10.3390/children8060433

Source DB:  PubMed          Journal:  Children (Basel)        ISSN: 2227-9067


  24 in total

Review 1.  Genetics of Kawasaki disease: what we know and don't know.

Authors:  Yoshihiro Onouchi
Journal:  Circ J       Date:  2012-06-07       Impact factor: 2.993

2.  Unexpected role for the B cell-specific Src family kinase B lymphoid kinase in the development of IL-17-producing γδ T cells.

Authors:  Renee M Laird; Karen Laky; Sandra M Hayes
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

3.  Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.

Authors:  Hiromichi Hamada; Hiroyuki Suzuki; Yoshihiro Onouchi; Ryota Ebata; Masaru Terai; Shigeto Fuse; Yoshitomo Okajima; Shunji Kurotobi; Katsuki Hirai; Takashi Soga; Yukiko Ishiguchi; Yoshiaki Okuma; Nobuyuki Takada; Masaaki Yanai; Junichi Sato; Mami Nakayashiro; Mamoru Ayusawa; Eiichi Yamamoto; Yuichi Nomura; Yuya Hashimura; Kazunobu Ouchi; Hiroshi Masuda; Shinichi Takatsuki; Keiichi Hirono; Tadashi Ariga; Takashi Higaki; Akio Otsuki; Moe Terauchi; Reiko Aoyagi; Takatoshi Sato; Yasuhisa Fujii; Tadami Fujiwara; Hideki Hanaoka; Akira Hata
Journal:  Lancet       Date:  2019-03-07       Impact factor: 79.321

4.  Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.

Authors:  Jun Abe; Ryota Ebata; Toshiaki Jibiki; Kumi Yasukawa; Hirohisa Saito; Masaru Terai
Journal:  J Allergy Clin Immunol       Date:  2008-10-19       Impact factor: 10.793

5.  Autoimmune disease-associated haplotypes of BLK exhibit lowered thresholds for B cell activation and expansion of Ig class-switched B cells.

Authors:  Kim R Simpfendorfer; Brandon E Armstead; Andrew Shih; Wentian Li; Mark Curran; Nataly Manjarrez-Orduño; Annette T Lee; Betty Diamond; Peter K Gregersen
Journal:  Arthritis Rheumatol       Date:  2015-11       Impact factor: 10.995

6.  Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.

Authors:  Donato Rigante; Piero Valentini; Daniela Rizzo; Andrea Leo; Gabriella De Rosa; Roberta Onesimo; Alessia De Nisco; Donatella Francesca Angelone; Adele Compagnone; Angelica Bibiana Delogu
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

7.  Combination of prednisolone and cyclosporin A as third-line therapy for refractory Kawasaki disease: a case study.

Authors:  Masamune Higashigawa; Tomomi Nakamura; Tomoki Hattori; Ayako Yoshino; Mitsue Ito; Ryoji Ichimi
Journal:  Minerva Pediatr       Date:  2019-12-11       Impact factor: 1.312

8.  Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.

Authors:  Ewoud B Compeer; Willemijn Janssen; Annet van Royen-Kerkhof; Marielle van Gijn; Joris M van Montfrans; Marianne Boes
Journal:  Oncotarget       Date:  2015-05-10

9.  Systematic confirmation study of GWAS-identified genetic variants for Kawasaki disease in a Chinese population.

Authors:  Jiao Lou; Rong Zhong; Na Shen; Xu-zai Lu; Jun-tao Ke; Jia-yu Duan; Yan-qi Qi; Yu-jia Wang; Qing Zhang; Wei Wang; Fang-qi Gong; Xiao-ping Miao
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

10.  A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki disease.

Authors:  Ho-Chang Kuo; Yu-Wen Hsu; Chung-Min Wu; Shawn Hsiang-Yin Chen; Kuo-Sheng Hung; Wei-Pin Chang; Kuender D Yang; Kai-Sheng Hsieh; Wei-Chiao Chen; Yoshihiro Onouchi; Wei-Chiao Chang
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.